Evaluation of semi-interpenetrating polymer networks composed of chitosan and poloxamer for wound dressing application.
We have elsewhere reported the work on the preparation of semi-interpenetrating polymer networks (SIPNs) composed of chitosan (CS) and poloxamer to improve the mechanical strength of CS sponge. This study focuses on evaluation of the CS/poloxamer SIPNs to intend for wound dressing application and the efficacy of dehydroepiandrosterone (DHEA)-loaded CS/poloxamer SIPNs in the wound model studies. The properties required for ideal wound dressing, such as equilibrium water content (EWC), water absorption (A(w)), water vapor transmission rate (WVTR), and evaporative water loss, were examined. The CS/poloxamer SIPNs were found to have a water content of 90% of their weight which could prevent the wound bed from accumulation of exudates and also have excellent water adsorption. The WVTR of CS/poloxamer SIPNs was found to be 2,508.2+/-65.7gm(-2)day(-1), indicating that the SIPNs can maintain a moist environment over wound bed in moderate to heavily exuding wound which enhances epithelial cell migration during the healing process. Also, the CS/poloxamer SIPNs in vitro assessment showed proper biodegradation and low cytotoxicity for wound dressing application. The wound healing efficacy of CS/poloxamer SIPNs as a wound dressing was evaluated on experimental full thickness wounds in a mouse model. It was found that the wounds covered with CS/poloxamer SIPNs or DHEA-loaded CS/poloxamer SIPNs were completely filled with new epithelium without any significant adverse reactions after 3 weeks. The results thus indicate that CS/poloxamer SIPNs could be employed in the future as potential wound dressing materials.
Kim
I Y
IY
School of Agricultural Biotechnology, Seoul National University, Seoul 151-921, South Korea.
Yoo
M K
MK
Seo
J H
JH
Park
S S
SS
Na
H S
HS
Lee
H C
HC
Kim
S K
SK
Cho
C S
CS
D000327:Adsorption; D000818:Animals; D001458:Bandages; D001672:Biocompatible Materials; D002056:Burns / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000737:chemistry* / Q000633:toxicity; D003687:Dehydroepiandrosterone / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004337:Drug Carriers; D004339:Drug Compounding; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D006868:Hydrolysis; D015603:Keratinocytes / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D041681:NIH 3T3 Cells; D020442:Poloxamer / Q000737:chemistry* / Q000633:toxicity; D012867:Skin / Q000187:drug effects / Q000473:pathology; D014835:Volatilization; D014867:Water / Q000737:chemistry; D014945:Wound Healing / Q000187:drug effects*
D001672:Biocompatible Materials; D004337:Drug Carriers; D014867:Water; D020442:Poloxamer; D003687:Dehydroepiandrosterone; D048271:Chitosan